Ligand Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is LGND moving today?
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LGND.
LGND insider activity
Ligand Pharmaceuticals Inc
4 insiders bought in the last 90 days
Net selling: -$25.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-06-12 | Haas Jason | Insider | sell | $256.08 | 3,461 | 4,981 | $886K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Haas Jason | Insider | sell | $255.01 | 3,000 | 8,442 | $765K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Haas Jason | Insider | buy | $51.56 | 1,000 | 11,442 | $52K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Haas Jason | Insider | buy | $51.56 | 3,000 | 10,442 | $155K | SEC Form 4 |
| 2026-06-12 | 2026-06-11 | Aryeh Jason | Insider | sell | $250.00 | 4,500 | 102,580 | $1.1M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 143 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moLGND contract awards, year to date.
Public federal awards linked to this ticker.
LGND lobbying filings, year to date.
Registered lobbying filings matched to Ligand Pharmaceuticals Inc.